Certain Estrogen-Androgen Combination Drugs; Drugs for Human Use; Drug Efficacy Study Implementation; Amendment and Opportunity for Hearing

Dr. Donna Shoupe, a professor of Obstetrics and Gynecology at the University of Southern California School of Medicine, argues that estrogen-androgen combination drugs are vital for treating various menopausal symptoms and conditions like osteoporosis. She emphasizes the need for individualized hormone therapy and urges the FDA to keep these medications available to provide patients with necessary treatment options.

Dr. Lawrence G. Raisz, a professor and director at the University of Connecticut Center for Osteoporosis, argues in favor of maintaining the availability of estrogen-androgen combination drugs. He highlights their clinical benefits for bone density and formation in postmenopausal women who do not respond well to estrogen alone, noting that the combination pill also improves patient compliance.

Dr. James A. Simon, a clinical professor at George Washington University, argues against the FDA's decision to deny an ANDA for ESTRATEST® Brand Tablets. He contends that the FDA has reached inaccurate conclusions regarding the patient population for estrogen-androgen combination therapy and emphasizes the clinical necessity of these drugs for women who do not achieve symptom relief with estrogen alone.

Dr. Christopher Longcope, a professor of Obstetrics & Gynecology at the University of Massachusetts Medical Center, argues against the FDA's decision to discontinue combined estrogen/androgen drugs. He provides clinical evidence that these combination therapies are effective for improving bone density, psychological symptoms, and vasomotor symptoms in postmenopausal women compared to estrogen alone.